Stock listing

NASDAQ:ENVB Enveric Biosciences, Inc. Stock

Home listing (NASDAQ) of Enveric Biosciences, Inc.

Follow Enveric Biosciences, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ENVB

$1.35 USD -0.07 (-4.9%)

Close on Nov 20, 2026

Past year -76.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.33 – $1.49 USDNov 20, 2026
Volume
62,193 sharesNov 20, 2026
Market cap
$6.04M USDAt the close on Nov 20, 2026 · price × 4.48M shares outstanding
52-week range
$1.17 – $13.25 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$84,989 USDMedian day 42,959 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Enveric Biosciences, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ENVB · Home$1.35 USD-0.07 (-4.9%)62,193$1.38$1.49$1.33$1.42Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ENVB · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.35-0.07-4.9%$1.38$1.49$1.3362,193
$1.42+0.01+0.7%$1.479$1.479$1.3637,009
$1.41-0.03-2.1%$1.43$1.475$1.4114,147
$1.44-0.075-5.0%$1.51$1.54$1.4434,608
$1.515-0.005-0.3%$1.52$1.55$1.5117,243
$1.52+0.03+2.0%$1.53$1.54$1.4732,237
$1.49-0.02-1.3%$1.381$1.579$1.3819,975
$1.51+0.07+4.9%$1.47$1.53$1.45538,140
$1.44+0.016+1.1%$1.41$1.47$1.4118,994
$1.424+0.024+1.7%$1.39$1.46$1.3810,393
$1.40-0.06-4.1%$1.46$1.46$1.3739,383
$1.46-0.04-2.7%$1.58$1.58$1.4335,559
$1.50+0.05+3.4%$1.45$1.51$1.4143,101
$1.45+0.02+1.4%$1.41$1.54$1.4128,845
$1.43-0.03-2.1%$1.47$1.481$1.4011,982
$1.46-0.01-0.7%$1.43$1.49$1.4227,933
$1.47+0.05+3.5%$1.485$1.489$1.3819,166
$1.42+0.04+2.9%$1.356$1.44$1.35656,485
$1.38-0.02-1.4%$1.40$1.41$1.3029,335
$1.40-0.06-4.1%$1.44$1.505$1.3933,300
$1.46-0.05-3.3%$1.51$1.57$1.4435,100
$1.51+0.07+4.9%$1.465$1.588$1.4384,500
$1.44+0.05+3.6%$1.375$1.445$1.37531,300
$1.39+0.01+0.7%$1.38$1.425$1.3631,500
$1.38-0.01-0.7%$1.35$1.442$1.3522,500
$1.39+0.02+1.5%$1.37$1.438$1.3521,200
$1.37-0.03-2.1%$1.38$1.45$1.33162,800
$1.40-0.07-4.8%$1.43$1.49$1.38102,100
$1.47+0.02+1.4%$1.43$1.52$1.40114,600
$1.45-0.07-4.6%$1.48$1.495$1.4450,200
$1.52+0.025+1.7%$1.47$1.531$1.4664,900
$1.495+0.025+1.7%$1.45$1.51$1.4541,400
$1.47-0.04-2.6%$1.53$1.53$1.4351,000
$1.51+0.03+2.0%$1.46$1.53$1.4554,300
$1.48+0.02+1.4%$1.51$1.53$1.4672,900
$1.46-0.025-1.7%$1.455$1.48$1.4183,600
$1.485+0.035+2.4%$1.44$1.53$1.42157,100
$1.45-0.02-1.4%$1.46$1.48$1.42345,800
$1.47-0.03-2.0%$1.51$1.56$1.4554,600
$1.50-0.045-2.9%$1.522$1.53$1.4838,200
$1.545-0.02-1.3%$1.57$1.58$1.47884,700
$1.565+0.025+1.6%$1.576$1.60$1.52113,400
$1.54-0.02-1.3%$1.54$1.608$1.5246,300
$1.56-0.06-3.7%$1.64$1.649$1.5551,300
$1.62+0.03+1.9%$1.62$1.649$1.519158,300
$1.59+0.10+6.7%$1.493$1.64$1.489169,600
$1.49+0.03+2.1%$1.45$1.54$1.4551,600
$1.46-0.02-1.4%$1.47$1.53$1.4475,300
$1.48+0.06+4.2%$1.423$1.538$1.41104,200
$1.42-0.04-2.7%$1.45$1.48$1.4238,700
$1.46+0.005+0.3%$1.45$1.46$1.4211,500
$1.455+0.035+2.5%$1.48$1.48$1.4029,800
$1.42+0.03+2.2%$1.38$1.452$1.3851,500
$1.39-0.05-3.5%$1.40$1.45$1.3656,742
$1.440.000.0%$1.47$1.47$1.37442,959
$1.44+0.07+5.1%$1.40$1.44$1.3721,276
$1.370.000.0%$1.39$1.39$1.3520,993
$1.370.000.0%$1.35$1.38$1.3338,529
$1.370.000.0%$1.41$1.41$1.3422,213
$1.370.000.0%$1.371$1.39$1.3436,701
$1.37-0.09-6.2%$1.47$1.52$1.17403,135
$1.46+0.05+3.5%$1.44$1.49$1.39964,794
$1.41-0.02-1.4%$1.44$1.471$1.3758,200
$1.43+0.04+2.9%$1.40$1.44$1.3889,150
$1.39+0.08+6.1%$1.34$1.39$1.29132,766

Splits

7 splits since 2008 · NASDAQ:ENVB · every price before a split is adjusted for it

DayRatioWhat
1-for-12Consolidation
1-for-15Consolidation
1-for-50Consolidation
1-for-4Consolidation
1-for-25Consolidation
1-for-17.61Consolidation
1-for-10Consolidation
Ticker
NASDAQ:ENVB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Enveric Biosciences, Inc. news

Enveric Biosciences, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
33 in the last 12 months · 149 in all · newest Nov 13, 2026 · oldest 2021
Decks
19 decks · latest Jun 9, 2026

Where Enveric Biosciences, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ENVB · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ENVBBOATSUnited StatesUSD
gettex:SLZ0gettexGermanyEUR
Frankfurt:SLZ0FrankfurtGermanyEUR
Munich:SLZ0MunichGermanyEUR
Stuttgart:SLZStuttgartGermanyEUR

Valuation

Price/book 1.1× against a median of 2.1×: 4th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$429,455 USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.1×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.76

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Enveric Biosciences, Inc. · NASDAQ:ENVBUS$6.04MUS$429,455n/an/an/a1.1×n/a0.0×0.76
FibroBiologics, Inc. · NASDAQ:FBLGUS$6.34MUS$5.17Mn/an/an/a3.5×n/a0.0×0.34
GT Biopharma, Inc. · NASDAQ:GTBPUS$6.33M−US$3.60Mn/an/an/a0.8×n/a0.0×1.57
Kyntra Bio, Inc. · NASDAQ:KYNBUS$6.32M−US$33.97Mn/a−6.4×n/an/a−326.0%n/a1.58
Acurx Pharmaceuticals, Inc. · NASDAQ:ACXPUS$6.30M−US$3.35Mn/an/an/a0.9×n/a0.0×1.31
TrivarX Limited · ASX:TRIUS$6.11MUS$4.58Mn/an/an/a0.6×n/a0.0×n/a
Medicofarma Biotech Spolka Akcyjna · NEWCONNECT:MDBUS$6.03MUS$6.03Mn/a314×n/a5.4×n/a0.0×n/a
Addex Therapeutics Ltd · SIX:ADXNUS$5.96MUS$5.13Mn/a68.2×n/a2.6×n/a0.0×n/a
Argenica Therapeutics Ltd · ASX:AGNUS$5.95MUS$1.74Mn/an/an/a1.5×n/a0.0×n/a
Marvel Biosciences Corp · TSXV:MRVLUS$5.91MUS$6.04Mn/an/an/an/an/an/a0.91
Exicure, Inc. · NASDAQ:XCURUS$5.89MUS$4.67Mn/an/an/a3.1×n/a0.0×0.49
Median of the othersUS$6.07MUS$4.62M68.2×2.1×−326.0%0.0×1.11

Team and board

Officers

OfficerRole
Joseph TuckerChief Executive Officer, Director
Kevin CoveneyChief Financial Officer
Jillian HagelVice President, Innovation

Board

DirectorRole
Michael D. WebbBoard Chair
Frank PasqualoneDirector, Chair of Compensation and Nominating Committees
George KeglerDirector, Chair of the Audit Committee
Joseph TuckerChief Executive Officer, Director
Marcus SchabackerDirector, Chair of Science and Technology Committee
Sheila DeWittDirector

Events

QuarterResultsShare move
Q3 2026Nov 13, 2026−5.3%
Q2 2026Aug 14, 2026−2.0%
Q1 2026May 19, 2026+2.3%
Q4 2025Mar 27, 2026−3.8%
Q3 2025Nov 14, 2025−9.0%
Q2 2025Aug 14, 2025−0.9%
Q1 2025May 13, 2025 · Before open+5.2%
Q4 2024Mar 28, 2025 · After close−5.4%
Q3 2024Nov 14, 2024 · After close−8.1%
Q2 2024Aug 12, 2024 · After close+1.4%
All 20 quarters
QuarterResultsShare move
Q1 2024May 15, 2024 · After close+14.2%
Q4 2023Mar 26, 2024 · Before open+0.9%
Q3 2023Nov 13, 2023 · After close−1.3%
Q2 2023Aug 11, 2023 · After close−1.5%
Q1 2023May 15, 2023 · Before open+3.5%
Q4 2022Mar 31, 2023 · After close−4.0%
Q3 2022Nov 14, 2022 · After close−0.6%
Q2 2022Aug 12, 2022 · After close−1.4%
Q1 2022May 13, 2022 · After close+2.5%
Q4 2021Mar 31, 2022 · After close−5.3%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (June 2026)Investor deck15 slidesJun 9, 2026
Investor Presentation (January 2026)Investor deck17 slidesJanuary 2026
Investor Presentation (August 2025)Investor deck14 slidesAug 29, 2025
Investor Presentation (August 2025)Investor deck15 slidesAugust 2025
Investor Presentation (February 2025)Investor deck15 slidesFebruary 2025
Investor Presentation (January 2025)Investor deck15 slidesJanuary 2025
Investor Presentation (August 2024)Investor deck15 slidesAug 21, 2024
Investor Presentation (January 2024)Investor deck21 slidesJanuary 2024
Investor Presentation (August 2023)Investor deck19 slidesAug 25, 2023
BIO 2023Conference19 slidesJun 6, 2023
All 19 decks
DeckKindSlidesDate
Investor Presentation (April 2023)Investor deck18 slidesApr 13, 2023
Investor Presentation (October 2022)Investor deck15 slidesOct 24, 2022
Investor Presentation (September 2022)Investor deck24 slidesSep 14, 2022
Investor Presentation (May 2022)Investor deck21 slidesMay 24, 2022
Investor Presentation (March 2022)Investor deck19 slidesMarch 2022
Investor Presentation (October 2021)Investor deck26 slidesOctober 2021
Investor Presentation (September 2021)Investor deck24 slidesSep 17, 2021
Merger or Acquisition (June 2021)Merger or acquisition28 slidesJun 8, 2021
Investor Presentation (March 2021)Investor deck19 slidesMarch 2021

Open Decks

Financings

RaiseDate
Private placement of shares of common stock (or pre-funded warrants) with Series I and short-term Series J warrants
Closed: US$5M raised · US$2.25 a share · Warrants at US$2 · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Product development, working capital and general corporate purposes
Apr 17, 2026
Registered direct offering of shares of common stock with unregistered series G and series H warrants
Closed: US$1.5M raised · US$4.41 a share · Warrants at US$4.16 · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Product development, working capital and general corporate purposes
Jan 28, 2026
Warrant exercise of outstanding warrants exercised for common stock
Closed: US$3.1M raised · US$7.05 a share · Warrants at US$7.05 · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Product development, working capital and general corporate purposes
Dec 12, 2025
Warrant exercise of series A and series B warrants exercised for common stock
Closed: US$2.2M raised · US$0.915 a share · Warrants at US$0.915 · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Product development, working capital and general corporate purposes
Sep 18, 2025
Public offering of common stock (or common stock equivalents) with Series A and Series B warrants
Closed: US$5M raised · US$3 a share · Warrants at US$3 · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Product development, working capital and general corporate purposes
Feb 3, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000039.9M39.9M43.0M48.6M36.1M
Cost of revenue200.9K337.5K408.0K435.2K681.6K120.9K31.8M34.0M38.4M29.2M
Gross profit-200.9K-337.5K-408.0K-435.2K-681.6K-120.9K8.15M8.98M10.2M6.93M
Research and development2.78M2.84M7.25M8.03M4.79M174.1K55.1K
Selling, general and administrative5.79M6.45M8.85M11.6M20.5M5.32M2.30M10.8M18.5M9.36M
Operating income-8.77M-9.63M-16.4M-27.4M-64.6M-5.62M-2.30M-7.15M-10.9M-5.38M
Depreciation and amortization200.9K337.5K344.0K327.9K656.6K120.9K2.27M2.90M3.22M1.36M
EBITDA-8.57M-9.29M-16.1M-27.1M-64.0M-5.50M-31.2K-4.24M-7.68M-4.02M
Interest expense1063.71K5.25K10.3K445.3K81.8K729.9K575.0K751.1K
Income before tax-8.77M-9.57M-17.3M-20.0M-56.4M-6.86M-5.22M-10.5M-11.5M-6.53M
Income tax3.36M8.93K28.9K-1.49M-7.45M-477.7K388.7K6.35M-2.39M-3.75M
Net income-8.77M-9.57M-17.3M-18.5M-49.0M-6.86M-2.41M-16.9M-9.07M-2.78M
Earnings per share, basic-36.24-228.48-121.29-13.00-103.69-1.19-2.83-20.47-0.75-0.21
Earnings per share, diluted-36.24-228.48-121.29-13.00-2.07-1.19-2.83-20.47-0.75-0.21

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents4.68M2.24M2.29M17.7M17.4M1.58M431.4K1.37M4.88M1.38M
Short-term investments82.9K
Receivables224.6K6.38M6.38M7.87M8.84M8.06M
Current assets4.94M2.73M3.58M18.4M17.7M2.28M108.8K10.1M14.6M10.1M
Property, plant and equipment159.2K305.8K507.4K677.5K294.4K83.1K58.9K95.0K100.2K
Goodwill379.7K1.59M13.7M13.7M13.7M21.9M17.1M
Total assets5.10M3.08M4.30M19.6M26.7M4.10M108.8K29.6M52.2M39.5M
Accounts payable581.0K521.7K1.22M463.3K683.4K681.3K4.70M4.38M5.32M5.13M
Current liabilities918.4K1.49M2.34M4.00M2.74M681.3K13.5M14.7M30.4M12.7M
Long-term debt01.13M1.54M
Total debt63.8K176.3K4.88M5.62M5.21M6.68M5.44M
Total liabilities918.4K1.49M2.34M4.00M4.41M681.3K1.92M18.9M32.7M27.8M
Shareholders' equity4.18M1.59M1.96M14.7M22.3M3.42M-1.81M-65.5K19.4M11.7M
Shares outstanding1.06M56.5K182.6K2.08M651.9K10.1M5.31M1.69M18.2M13.9M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-8.14M-7.73M-14.1M-17.1M-11.5M-3.89M-647.9K-2.57M-2.74M-2.70M
Capital spending-30-5.18K-584.2K-189.7K-44.1K-84.3K-189.7K-4.84K-3.69M
Free cash flow-8.14M-7.73M-14.1M-17.7M-11.6M-3.93M-647.9K-2.57M-2.75M-6.39M
Cash from investing11.7K-584.2K2.19M-44.1K-284.3K-3.64M-169.9K-6.59M
Cash from financing10.6M7.67M-1.34M18.2M24.9M5.53M560.0K2.69M6.41M8.80M
Dividends paid-3.36M-2.09T-2.09B
Share buybacks1.08M-1.05M02.09T
Change in cash2.44M-47.0K-15.4M367.9K15.8M1.53M-70.0K-3.51M3.50M-498.1K

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
8-K · Current reportNov 13, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeNov 3, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportAug 14, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
8-K · Current reportJun 9, 2026Current reportSEC
424B5 · ProspectusJun 9, 2026Offer documentSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportJun 8, 2026Current reportSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMay 29, 2026Offer documentSEC
8-K · Current reportMay 29, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
8-K · Current reportMay 15, 2026ResultsSEC
DMay 4, 2026Other filingsSEC
8-K · Current reportApr 30, 2026Current reportSEC
DEFA14A · Additional proxy materialApr 30, 2026Meeting noticeSEC
EFFECT · Notice that a registration is effectiveApr 30, 2026Other filingsSEC
424B3 · ProspectusApr 29, 2026Offer documentSEC
CORRESP · Letter to the SECApr 28, 2026Other filingsSEC
UPLOAD · Letter from the SECApr 27, 2026Other filingsSEC
S-3 · Registration statementApr 23, 2026Offer documentSEC
8-K · Current reportApr 17, 2026Material contractSEC
ARS · Annual report to shareholdersApr 14, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 14, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 14, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 3, 2026Meeting noticeSEC
10-K · Annual reportMar 27, 2026Annual reportSEC
8-K · Current reportMar 27, 2026ResultsSEC
424B3 · ProspectusFeb 18, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 18, 2026Other filingsSEC
CORRESP · Letter to the SECFeb 17, 2026Other filingsSEC
UPLOAD · Letter from the SECFeb 17, 2026Other filingsSEC
DFeb 11, 2026Other filingsSEC
S-1 · Registration statementFeb 9, 2026Offer documentSEC
8-K · Current reportFeb 6, 2026Current reportSEC
424B5 · ProspectusFeb 6, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeFeb 4, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 2, 2026Big-stake noticeSEC
8-K · Current reportJan 28, 2026Material contractSEC
424B5 · ProspectusJan 28, 2026Offer documentSEC
8-K · Current reportJan 9, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 5, 2026Big-stake noticeSEC
424B3 · ProspectusDec 31, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 31, 2025Other filingsSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
CORRESP · Letter to the SECDec 29, 2025Other filingsSEC
DDec 23, 2025Other filingsSEC
UPLOAD · Letter from the SECDec 23, 2025Other filingsSEC
S-3 · Registration statementDec 22, 2025Offer documentSEC
S-8 · Registration statement for employee plansDec 19, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeDec 17, 2025Big-stake noticeSEC
8-K · Current reportDec 12, 2025Material contractSEC
8-K · Current reportDec 11, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 10, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 10, 2025Big-stake noticeSEC
424B3 · ProspectusDec 9, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 9, 2025Other filingsSEC
CORRESP · Letter to the SECDec 8, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeDec 5, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeDec 5, 2025Big-stake noticeSEC
S-3/A · Registration statement, amendedDec 5, 2025Offer documentSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
8-K · Current reportNov 14, 2025Current reportSEC
8-K · Current reportNov 14, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeNov 13, 2025Big-stake noticeSEC
DEF 14A · Proxy statementOct 27, 2025Meeting noticeSEC
8-K · Current reportOct 23, 2025Current reportSEC
PRE 14A · Preliminary proxy statementOct 10, 2025Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeOct 3, 2025Big-stake noticeSEC
DOct 3, 2025Other filingsSEC
UPLOAD · Letter from the SECSep 30, 2025Other filingsSEC
S-3 · Registration statementSep 29, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeSep 24, 2025Big-stake noticeSEC
8-K · Current reportSep 18, 2025Material contractSEC
8-K · Current reportSep 2, 2025Current reportSEC
8-K · Current reportAug 29, 2025Current reportSEC
8-K · Current reportAug 29, 2025Current reportSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportAug 14, 2025ResultsSEC
8-K · Current reportJun 3, 2025Meeting outcomeSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
4 · Change in ownershipMay 12, 2025Insider tradeSEC
4 · Change in ownershipMay 12, 2025Insider tradeSEC
4 · Change in ownershipMay 12, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveApr 18, 2025Other filingsSEC
CORRESP · Letter to the SECApr 16, 2025Other filingsSEC
ARS · Annual report to shareholdersApr 16, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 15, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 15, 2025Meeting noticeSEC
8-K · Current reportApr 14, 2025Current reportSEC
S-3/A · Registration statement, amendedApr 10, 2025Offer documentSEC
PRE 14A · Preliminary proxy statementApr 4, 2025Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 2, 2025Big-stake noticeSEC
8-K · Current reportMar 31, 2025ResultsSEC
10-K · Annual reportMar 28, 2025Annual reportSEC
S-8 · Registration statement for employee plansMar 24, 2025Offer documentSEC
8-K · Current reportMar 6, 2025Current reportSEC
8-K · Current reportFeb 26, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 5, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 4, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 4, 2025Big-stake noticeSEC
8-K · Current reportFeb 3, 2025Material contractSEC
424B4 · ProspectusFeb 3, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 31, 2025Other filingsSEC
S-1/A · Registration statement, amendedJan 30, 2025Offer documentSEC
CORRESP · Letter to the SECJan 30, 2025Other filingsSEC
S-1/A · Registration statement, amendedJan 30, 2025Offer documentSEC
8-K/A · Current report, amendedJan 27, 2025Current reportSEC
8-K · Current reportJan 21, 2025Meeting outcomeSEC
UPLOAD · Letter from the SECJan 21, 2025Other filingsSEC
S-1 · Registration statementJan 14, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeJan 6, 2025Big-stake noticeSEC
8-K · Current reportJan 3, 2025Current reportSEC
UPLOAD · Letter from the SECDec 19, 2024Other filingsSEC
DEF 14A · Proxy statementDec 18, 2024Meeting noticeSEC
PRER14ADec 12, 2024Other filingsSEC
PRE 14A · Preliminary proxy statementNov 27, 2024Meeting noticeSEC
8-K · Current reportNov 22, 2024Current reportSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
8-K · Current reportNov 14, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
8-K · Current reportNov 12, 2024Material contractSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
424B4 · ProspectusSep 12, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 12, 2024Other filingsSEC
CORRESP · Letter to the SECSep 10, 2024Other filingsSEC
UPLOAD · Letter from the SECSep 9, 2024Other filingsSEC
S-1 · Registration statementSep 4, 2024Offer documentSEC
8-K · Current reportAug 22, 2024Current reportSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
8-K · Current reportAug 12, 2024ResultsSEC
8-K · Current reportJul 15, 2024Material contractSEC
UPLOAD · Letter from the SECJul 12, 2024Other filingsSEC
S-3 · Registration statementJul 8, 2024Offer documentSEC
3 · Initial statement of ownershipJun 3, 2024Insider tradeSEC
8-K · Current reportMay 29, 2024Meeting outcomeSEC
8-K · Current reportMay 23, 2024Current reportSEC
8-K · Current reportMay 17, 2024Current reportSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
424B5 · ProspectusMay 3, 2024Offer documentSEC
8-K · Current reportMay 3, 2024Material contractSEC
ARS · Annual report to shareholdersApr 16, 2024Annual reportSEC
DEF 14A · Proxy statementApr 16, 2024Meeting noticeSEC
8-K · Current reportMar 28, 2024Current reportSEC
8-K · Current reportMar 26, 2024ResultsSEC
10-K · Annual reportMar 25, 2024Annual reportSEC
8-K · Current reportMar 19, 2024Current reportSEC
424B5 · ProspectusMar 11, 2024Offer documentSEC
8-K · Current reportMar 11, 2024Material contractSEC
8-K · Current reportFeb 29, 2024Current reportSEC
4 · Change in ownershipFeb 26, 2024Insider tradeSEC
4 · Change in ownershipFeb 26, 2024Insider tradeSEC
4 · Change in ownershipFeb 26, 2024Insider tradeSEC
8-K · Current reportFeb 21, 2024Current reportSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
8-K · Current reportFeb 9, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 6, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 5, 2024Big-stake noticeSEC
424B3 · ProspectusJan 24, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 23, 2024Other filingsSEC
CORRESP · Letter to the SECJan 19, 2024Other filingsSEC
UPLOAD · Letter from the SECJan 16, 2024Other filingsSEC
S-3 · Registration statementJan 11, 2024Offer documentSEC
8-K · Current reportJan 8, 2024Current reportSEC
8-K · Current reportJan 3, 2024Current reportSEC
8-K · Current reportDec 29, 2023Material contractSEC
8-K · Current reportDec 28, 2023Current reportSEC
8-K · Current reportDec 27, 2023Current reportSEC
424B4 · ProspectusDec 6, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 6, 2023Other filingsSEC
8-K · Current reportDec 5, 2023Current reportSEC
CORRESP · Letter to the SECDec 4, 2023Other filingsSEC

This page holds 200 of 1,002 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Enveric Biosciences, Inc.’s releases · as of Nov 11, 2026

Common shares
4,475,884
Fully diluted
4,475,884

Fully diluted

LineSharesAs of
Common shares4,475,884Nov 11, 2026

Warrants and options

Lot
Warrants · US$2.00 · expiry not stated
Warrants · US$4.16 · expiry not stated
Warrants · US$7.05 · expiry not stated
Warrants · US$0.92 · expiry not stated
Warrants · US$3.00 · expiry not stated

Share count over time

CountShares
Nov 11, 20264,475,884

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Sio Capital Management, LLC330K7.4%US$490KSep 30, 2026
Ikarian Capital, LLC100K2.2%US$147KSep 30, 2026
Vanguard48,6961.1%US$71,583Sep 30, 2026
AdvisorShares Investments LLC43,7830.98%US$64,361Sep 30, 2026
Citadel41,3720.92%US$60,817Sep 30, 2026
Boothbay Fund Management, LLC30,1420.67%US$44,761Sep 30, 2026
StoneX Group Inc.27,9860.63%US$41,051Sep 30, 2026
Jane Street19,4440.43%US$28,874Sep 30, 2026
Geode Capital17,7940.40%US$26,156Sep 30, 2026
XTX Topco Ltd13,3660.30%US$19,648Sep 30, 2026
All 26 holders
HolderSharesOf the companyValueAs of
Two Sigma10,2300.23%US$15,192Sep 30, 2026
SBI Securities Co., Ltd.3,0890.07%US$4,587Sep 30, 2026
Farther Finance Advisors, LLC3,0000.07%US$4,455Sep 30, 2026
Tower Research Capital LLC (TRC)2,0060.04%US$2,979Sep 30, 2026
Jones Financial Companies Lllp1,0000.02%US$1,500Sep 30, 2026
UBS434<0.01%US$643Sep 30, 2026
BlackRock51<0.01%US$76Sep 30, 2026
Root Financial Partners, LLC13<0.01%US$19Sep 30, 2026
Arax Advisory Partners8<0.01%US$12Sep 30, 2026
Fidelity2<0.01%US$3Sep 30, 2026
Morgan Stanley1<0.01%US$1Sep 30, 2026
Osaic Holdings, Inc.1<0.01%US$1Sep 30, 2026
Danske Bank A/S1<0.01%US$1Sep 30, 2026
Citigroup Inc1<0.01%US$1Sep 30, 2026
National Bank Of Canada1<0.01%US$1Sep 30, 2026
Wells Fargo1<0.01%US$1Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
AdvisorShares Psychedelics ETF35,4170.79%US$48,875Jun 30, 2026
Vanguard Extended Market Index Fund14,9120.33%US$20,579Jun 30, 2026
Fidelity Extended Market Index Fund11,5550.26%US$26,577May 31, 2026
Fidelity Nasdaq Composite Index Fund9110.02%US$2,095May 31, 2026

Big stakes

StakeStakeSharesDateFiling
Armistice Capital, LLC9.99%405KJun 30, 2026Schedule 13G
Sio Capital Management, LLC7.37%330KSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Frank Pasqualone
Other companies: Theravance Biopharma, Inc. (SVP, CHIEF BUSINESS OFFICER · May 14, 2014 – Nov 19, 2021 · Past); Innoviva, Inc. (Sr. Vice President, Operations · Jan 13, 2014 – Jan 23, 2014 · Past)
Director · Since at least Jul 13, 2022
Sol Meyer
Other companies: Fabric.AI, Inc. (Director · Jan 30, 2018 – May 28, 2020 · Past); BlastGard International Inc (Director · Mar 10, 2015 – Mar 18, 2015 · Past)
Director · Dec 30, 2020 – Feb 15, 2021 · Past
Barry Kostiner
Other companies: Legacy Education Alliance, Inc. (Chief Executive Officer, Director · May 4, 2021 – Mar 17, 2023 · Past)
Chief Financial Officer · Oct 17, 2018 – Oct 17, 2018 · Past
George Kegler
Other companies: Mallinckrodt Inc (EVP & CFO, Interim · Dec 6, 2018 – Jan 9, 2019 · Past)
Director, Chair of the Audit Committee · Since at least Dec 30, 2020
Greggory A Schneider
Other companies: Reliability Inc. (Chief Financial Officer, Director · Apr 5, 2012 – Apr 5, 2012 · Past)
Chief Financial Officer, Director · Aug 25, 2011 – Jul 25, 2012 · Past
John Van Buiten
Other companies: Gordon Pointe Acquisition Corp (Principal Accounting Officer · Since at least Mar 9, 2022)
Chief Financial Officer · Dec 30, 2020 – Mar 4, 2021 · Past
Joseph Tucker
Other companies: Lakewood-Amedex Biotherapeutics Inc. (Director · Since at least Apr 24, 2026)
Chief Executive Officer, Director · Since at least Sep 16, 2021
Marcus Schabacker
Other companies: Baxter International Inc. (CVP, Chief Scientific Officer · Jun 30, 2015 – Mar 6, 2017 · Past)
Director, Chair of Science and Technology Committee · Since at least Dec 30, 2020
Bradley George ThompsonDirector · Sep 16, 2021 – Sep 16, 2021 · Past
Brent KeltonChief Executive Officer · Dec 26, 2017 – Feb 5, 2019 · Past
All 19 people
PersonSeat
Frank PasqualoneDirector, Chair of Compensation and Nominating Committees · Since at least Jun 3, 2026
Jillian HagelVice President, Innovation · Since at least Sep 16, 2021
Kevin CoveneyChief Financial Officer · Since at least Mar 13, 2023
Michael D. WebbBoard Chair · Since at least Jun 13, 2022
Peter J FacchiniChief Innovation Officer · Since at least Jun 1, 2026
Robert G WilkinsChief Medical Officer · Dec 30, 2020 – Dec 30, 2020 · Past
Sheila DeWittDirector · Since at least Jun 3, 2026
Thoranath SukumaranDirector · Dec 11, 2018 – Dec 11, 2018 · Past
Venkatraman BalakrishnanDirector · Jun 28, 2016 – Feb 14, 2018 · Past

Open People

Log in to ask 6ix AI your own questions about Enveric Biosciences, Inc.